{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:02:58Z","timestamp":1792188178111,"version":"4.4.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Three mAbs targeting immune checkpoint proteins are available for the treatment of patients with melanoma, lung, and kidney cancer, and their use will likely expand in the future to additional tumor types. We here update the literature on the incidence and pathophysiology of endocrine toxicities induced by these agents, and discuss management guidance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Immune checkpoint inhibition may trigger autoimmune syndromes involving different organs, including several endocrine glands (pituitary, thyroid, adrenals, and endocrine pancreas). Hypophysitis is more frequently associated with ipilimumab, whereas the incidence of thyroid dysfunction is higher with nivolumab\/pembrolizumab. Primary adrenal insufficiency can rarely occur with either treatment. Autoimmune diabetes is very rare. As hypophysitis and adrenalitis may be life-threatening, endocrinological evaluation is essential particularly in patients developing fatigue and other symptoms consistent with adrenal insufficiency. Corticosteroids should be promptly used when hypophysitis-induced adrenal insufficiency or adrenalitis are diagnosed, but not in thyroiditis or diabetes. No impact of corticosteroids on the efficacy\/activity of immune checkpoint-inhibiting drugs is reported. Hormonal deficiencies are often permanent.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In absence of predicting factors, accurate information to patients provided by the oncology care team is essential for early diagnosis and to limit the consequences of checkpoint inhibition-related endocrine toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000293","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T13:09:52Z","timestamp":1461935392000},"page":"278-287","source":"Crossref","is-referenced-by-count":116,"title":["Endocrinological side-effects of immune checkpoint inhibitors"],"prefix":"10.1097","volume":"28","author":[{"given":"Francesco","family":"Torino","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, Chair of Medical Oncology, Tor Vergata University of Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore M.","family":"Corsello","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Pituitary Center, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV nonsmall-cell lung cancer: results from a randomized, double-blind, multicentre phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/jco.2012.30.15_suppl.8508","article-title":"Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III\/IV melanoma: 10\u200amg\/kg cohort interim results","volume":"30","author":"Hamid","year":"2012","journal-title":"J Clin Oncol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (antiprogrammed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced nonsmall-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmall-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of nonsmall cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R28-20230901","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): a randomised controlled trial","author":"Herbst","year":"2015","journal-title":"Lancet"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.3002","article-title":"Preliminary data from a multiarm expansion study of MEDI4736, an anti-PD-L1 antibody","volume":"32","author":"Segal","year":"2014","journal-title":"J Clin Oncol"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an antiprogrammed cell death-ligand 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC)","volume":"33","author":"Rizvi","year":"2015","journal-title":"J Clin Oncol"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-12-116","article-title":"Clinical experience with ipilimumab 3\u200amg\/kg: real world efficacy and safety data from an expanded access programme cohort","volume":"12","author":"Ascierto","year":"2014","journal-title":"J Transl Med"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/jco.2011.29.15_suppl.8511","article-title":"A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma","volume":"29","author":"Hodi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R39-20230901","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.seminoncol.2015.02.011","article-title":"Toxicity patterns with immunomodulating antibodies and their combinations","volume":"42","author":"Haanen","year":"2015","journal-title":"Semin Oncol"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R45-20230901","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R47-20230901","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-14-1457","article-title":"Immuno-oncology combinations: a review of clinical experience and future prospects","volume":"20","author":"Antonia","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R48-20230901","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R49-20230901","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"R50-20230901","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"R51-20230901","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"R52-20230901","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"R53-20230901","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocrine Rev"},{"key":"R54-20230901","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"R55-20230901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R56-20230901","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-010-9794-7","article-title":"Hyponatremia associated with ipilimumab-induced hypophysitis","volume":"29","author":"Barnard","year":"2012","journal-title":"Med Oncol"},{"key":"R57-20230901","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4158\/EP11273.OR","article-title":"Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series","volume":"18","author":"Min","year":"2012","journal-title":"Endocr Pract"},{"key":"R59-20230901","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin Oncol"},{"key":"R60-20230901","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol"},{"key":"R61-20230901","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"R62-20230901","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"R63-20230901","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"R64-20230901","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"R65-20230901","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production","volume":"11","author":"Laurent","year":"2013","journal-title":"J Transl Med"},{"key":"R66-20230901","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R67-20230901","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"R68-20230901","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R69-20230901","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced Graves\u2019 disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R70-20230901","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/thy.2013.0241","article-title":"Thyroid dysfunction as an unintended side effect of anticancer drugs","volume":"23","author":"Torino","year":"2013","journal-title":"Thyroid"},{"key":"R71-20230901","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdu577","article-title":"Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study","volume":"26","author":"Di Giacomo","year":"2015","journal-title":"Ann Oncol"},{"key":"R72-20230901","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","article-title":"Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)","volume":"60","author":"Di Giacomo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"R73-20230901","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"R74-20230901","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-013-2213-y","article-title":"Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)","volume":"72","author":"Corsello","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R75-20230901","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"R76-20230901","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/17512433.2016.1133289","article-title":"Endocrinopathies induced by immune-checkpoint inhibitors in advanced nonsmall cell lung cancer","volume":"9","author":"Rossi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001622-201607000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:22:30Z","timestamp":1693549350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201607000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000293","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}